Introducing our new and improved Hot Tort Report
Being industry experts, we pride ourselves on keeping our finger on the pulse on all things Multi District Litigation. This predominantly consists of providing our subscribers with competitive insights into where the money is being spent in hopes to inform your blueprint for advertising strategies.
We’ve been working hard on an algorithm to deliver more than just monthly TV spends and are proud to announce that we are ready to unveil our HTR 2.0.
This new list compiles an overview of dollars deployed on TV, Meta campaigns, PPC presence, and Whitehardt’s Institutional Insights indicator, which assigns a score to each tort based on what we, as leaders in the law firm advertising space, are witnessing across these various platforms.
The Hot Tort Report:
March 2025
The Hottest in Mass Tort Spending: February 2025
#1 Birth Control Injections
Featured Tort
Subscribe to the Hot Tort Report
What’s the Tort News?
Published: March, 2025. Advertising spend from multiple sources for a recent 30 day period.
If you have any questions, please contact Bails at bails@whitehardt.com
#1 Birth Control Injections
The Birth Control Injections mass tort held onto the top spot this month, despite a slight dip in TV advertising activity. Digital engagement remains strong, keeping Depo-Provera® lawsuits at the forefront of mass tort advertising.
This month brought two major developments:
- 27 cases in the Northern District of Florida were consolidated under Judge M. Casey Rodgers.
- Judge Rodgers held the first case management conference on 21 February, fast-tracking the process by establishing 5 pilot cases.
With cases already moving forward, firms looking to engage should act now.
CPA: $1,260 – $7,500
CPL: $630 – $3,750
For criteria, please contact us.
#2 Paraquat
The Paraquat mass tort surged from 7th place last month to 2nd this month, nearly doubling its total score as TV advertising activity and WHii engagement spiked.
Litigation is also accelerating. A recent CMO set key trial dates, with 6 cases planned to move forward in 2 phases: Phase 1 begins on 14 October 2025, and Phase 2 follows on 6 April 2026. With trials now on the calendar, this litigation is firing up fast.
CPA: $2,056
CPL: $925
Common Criteria: Diagnosis of Parkinson’s Disease or experiencing Parkinson’s-like symptoms after exposure to Paraquat.
#3 Roundup®
Despite a 2.2-point increase in total score, Roundup® slipped to 3rd place as Paraquat’s rapid growth pushed it down the rankings.
TV and PPC spending surged, while Meta remained strong. With widespread advertiser interest and steady engagement across platforms, Roundup® litigation continues to hold firm in the mass tort space.
CPA: $1,333
CPL: $800
For criteria, please contact us.
#4 Infant Formula
Climbing up a spot this month, the Infant Formula tort saw slight gains in WHii and TV activity, while Meta and PPC continue to drive most of the engagement.
A motion for summary judgment has been filed, which, if approved, could extinguish the flame for this litigation. For now, however, ad activity is heating up, and firms should take note.
Common Criteria: Premature child born after 2002, severe injuries related to diagnosis of NEC, was fed formula in hospital. Infant was fed cow-milk-based formula (okay if unsure of brand) AND was diagnosed with NEC in or after the year 2002. If not premature, infant was diagnosed with NEC within 3 months after birth AND had surgery.
For metrics such as CPA and CPL, please contact us.
#5 Diabetes Meds For Weight Loss
Like several others on this list, the Diabetes Medications for Weight Loss mass tort has seen increased activity through digital channels, with Meta engagement nearly doubling over the past month.
Now is the time for firms to position themselves effectively in this growing mass tort. Whitehardt can help you connect with claimants and maximize your reach where it matters.
CPA: $180 – $260
CPL: $90 – $130
Common Criteria: Took a prescription diabetes drug for weight loss (e.g. Ozempic, Mounjaro); discontinued use of the drug; and experienced one or more gastrointestinal disorders at least 30 days after your first dose
#6 AFFF
The AFFF mass tort saw one of the biggest shifts in Meta activity, climbing nearly 3 points in that category since last month, while PPC remained steady. With no movement in TV or WHii, the focus for firms who want to engage with this tort is currently on digital channels.
CPA: $3,500
CPL: $1,750
For criteria, please contact us.
#7 Processed Foods
New to the Hot Tort Report top 10, the Processed Foods mass tort is making an immediate impact, showing strong PPC, TV, and Meta activity.
Lawsuits allege that ultra-processed foods are designed to be addictive, fueling serious health consequences, especially in children. As more claims surface, this tort is just sparking up.
For metrics such as CPA, CPL, and common criteria, please contact us.
#8 Takata Airbag Recall
After dropping off the Hot Tort Report last month, the Takata Airbag Recall mass tort is making a comeback, driven almost entirely by TV advertising.
With Meta and PPC still inactive, firms are leaning into TV campaigns to reconnect with claimants in one of the most well-known product liability cases in recent history.
For metrics such as CPA, CPL, and common criteria, please contact us.
#9 California Wildfires
The California Wildfires mass tort held its 9th-place ranking, with PPC and WHii increasing as Meta dipped slightly.
As California residents begin the long process of rebuilding, legal action is only just beginning. With mounting lawsuits and claims of corporate negligence gaining traction, this tort is poised to expand in the months ahead. Firms looking to assist affected communities should act as soon as possible.
CPL: $350
For metrics such as CPA and criteria, please contact us.
#10 Hair Dye
This is another tort breaking into the top 10 for the first time after seeing a 2-point total increase this month.
This litigation centers on claims that long-term use of chemical hair dyes, particularly those with certain carcinogenic ingredients, has been linked to an increased risk of hormone-related cancers. With growing interest in digital platforms, this tort is one to watch.
For metrics such as CPA, CPL, and criteria, please contact us.
Mesothelioma
You may be noticing a tort missing from our new report. While Mesothelioma continues to dominate the competition when it comes to spend levels, Whitehardt finds that this tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game and patience when landing that ringer of a case. We believe that Meso will remain a constant for some time, but in regards to many of the other drugs and devices we focus on in this monthly report, we’ve decided to move it to its own category. If you are interested in hearing the latest news on Meso or how Whitehardt may be currently seeking these cases, you can contact us here.
Whitehardt will continue to track meso spending from month to month, so if you are interested in ongoing meso spending, please reach out to me directly. Going forward, we will be excluding meso from these tort reports.
